Last reviewed · How we verify
Ronapreve (CASIRIVIMAB)
Ronapreve (Casirivimab) is a monoclonal antibody developed by Regeneron Pharmaceuticals, Inc. It is used to treat COVID-19 and works by binding to the SARS-CoV-2 virus, preventing it from entering host cells. Ronapreve is a patented medication with FDA approval since 2020. Key safety considerations include potential allergic reactions and the risk of transmission of COVID-19 despite treatment. As a monoclonal antibody, Ronapreve is a large molecule, not a small molecule.
At a glance
| Generic name | CASIRIVIMAB |
|---|---|
| Sponsor | Regeneron Pharmaceuticals, Inc. |
| Modality | Monoclonal antibody |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2020 |
Approved indications
- COVID-19
Common side effects
Key clinical trials
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
- COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease (PHASE1,PHASE2)
- A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults (PHASE3)
- COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age (PHASE2)
- COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers (PHASE2)
- COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19 (PHASE1)
- COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ronapreve CI brief — competitive landscape report
- Ronapreve updates RSS · CI watch RSS
- Regeneron Pharmaceuticals, Inc. portfolio CI